Popular now
Accountancy group DJH increases regional revenue to £14m

Accountancy group DJH increases regional revenue to £14m

UK CEOs increase M&A activity to accelerate AI transformation, EY finds

UK CEOs increase M&A activity to accelerate AI transformation, EY finds

MHA appointed liquidator for Aberdeen workwear manufacturer

MHA appointed liquidator for Aberdeen workwear manufacturer

KPMG reveals new CMO
Image credit: Solvency II Wire

KPMG reveals new CMO

Register to get free articles

No spam Unsubscribe anytime

Want unlimited access? View Plans

Already have an account? Sign in

KPMG UK has appointed Fiona Thomas as the firm’s new chief medical officer within its life sciences practice.

Thomas will act as KPMG UK’s senior medical adviser to clients across the healthcare space globally.

She joins from international biopharmaceutical company Swedish Orphan Biovitrum where she was UK medical director, and has also previously held senior roles with Sanofi Pasteur MSD and Biogen.

Prior to her 14-year career in the pharmaceutical industry, Thomas practiced as a physician in critical care and anaesthesia.

Originally from Glasgow, Thomas studied Medicine at the University of Glasgow and is registered with a licence to practice with the UK General Medical Council.

She said: “I’m pleased to be joining KPMG UK at a time of incredible growth for our Life Sciences practice, and to be working with clients across the healthcare industry. Throughout my career I’ve always been passionate about finding solutions that will ultimately bring advancement in medical practice and more positive outcomes for patients.

“As CMO it’s my aim to ensure our clients globally receive the best possible advice so they can successfully operate within the pharmaceutical industry for the benefit of patients.”

Head of KPMG UK’s Life Sciences Practice, Adrian Griffiths, added: “Fiona brings incredible experience as a practitioner and through her successful career working closely with the world’s largest pharmaceutical companies.

“Her experience, network and expertise will be a great asset to our Life Sciences practice, and we look forward to our clients benefiting from Fiona’s unique skillset as a senior medical adviser.”

Previous Post
4 in 5 UK SMEs aren’t seeking finance to grow, ACCA finds

4 in 5 UK SMEs aren’t seeking finance to grow, ACCA finds

Next Post
KPMG to audit Phoenix Group from 2024

KPMG to audit Phoenix Group from 2024

Secret Link